TITLE

OREXO/KYOWA HAKKO KIRIN DISTRIBUTE KW-2246 FOR CANCER PAIN

PUB. DATE
March 2010
SOURCE
Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the joint distribution agreement signed between Kyowa Hakko Kirin Co. Ltd. and pharmaceutical firm Hisamitsu Pharmaceutical Co. Inc. Kyowa will primarily handle the approval process for the product in Japan. Under the terms of the agreement, the two companies will jointly distribute the cancer pain drug KW-2246 from Orexo AB.
ACCESSION #
48366832

 

Related Articles

  • Having the 'Nrf2' Switch Pays Off: Kirin Gives Reata $35M Up Front. Osborne, Randy // BioWorld Today;1/11/2010, Vol. 21 Issue 6, p1 

    The article reports on a contract signed by Reata Pharmaceuticals Inc. with Kyowa Hakko Kirin Co. Ltd. for the development of Nrf2-targeting bardoxolone. As part of the deal, Reata received 35 million U.S. dollars up front for development. Aside from being the prime mover behind all antioxidants...

  • Orexo's partner obtains positive results from Phase III breakthrough pain study.  // PharmaWatch: CNS;Sep2009, Vol. 8 Issue 9, p23 

    The article reports that the Japanese partner Kyowa Hakko Kirin Co. Ltd. of the pharmaceutical company Orexo AB in Sweden has achieved positive results of the Phase III trial of KW-2246 for the cure of pain in patients with cancer. It mentions that the drug is commercialized under the brand...

  • Parkinson's Update.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p8 

    The article offers news briefs related to Parkinson's disease. Sun Pharmaceutical Industries Ltd. has announced that U.S. Food and Drug Administration (FDA) has granted tentative approval on the new drug application of Orion's Stalevo tablets in the generic market. Intra-Cellular Therapies Inc....

  • Other News To Note.  // BioWorld Today;12/8/2010, Vol. 21 Issue 236, p4 

    This section offers news briefs on the biotechnology industry. A worldwide antibody discovery and development deal was signed by Apexigen Inc. with Centocor Research & Development Inc. The research collaboration between Dicerna Therapeutics Inc. and Kyowa Hakko Kirin Co. Ltd. has been expanded...

  • Other News To Note.  // BioWorld Today;11/27/2012, Vol. 23 Issue 229, p2 

    This section offers news briefs on the biopharmaceutical sector. A research agreement was signed between Activiomics Ltd. and Kyowa Hakko Kirin. Legal action was initiated by Amarantus BioSciences Inc. to delist its stock from the Berlin-Bremen Stock Exchange. Genzyme Corp. has received approval...

  • SWOT ANALYSIS.  // Kyowa Hakko Kirin Co., Ltd. SWOT Analysis;May2011, p5 

    The article offers a strength, weaknesses, opportunities and threats (SWOT) analysis for Kyowa Hakko Kirin (KHK) Co. Ltd., which manufactures and markets medical products and pharmaceuticals. Strengths include combined pharmaceutical and biotechnology assets and strengthening pharmaceutical...

  • Kyowa Hakko Kirin Co., Ltd. SWOT Analysis.  // Kyowa Hakko Kirin Co., Ltd. SWOT Analysis;Apr2012, p1 

    A business analysis of Kyowa Hakko Kirin Co. Ltd., which offers pharmaceuticals and biochemicals, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include its combined pharmaceutical and biotechnology assets. Weaknesses...

  • Other News To Note.  // BioWorld Today;8/1/2012, Vol. 23 Issue 148, p2 

    This section offers news briefs on the biotechnology industry as of August 1, 2012. An abbreviated new drug application was filed by Abon Pharmaceuticals LLC for its Clofarabine Injection. Beal Advisors was retained by AdeTherapeutics Inc. to evaluate strategic options for partnering and...

  • CLINIC ROUNDUP.  // BioWorld Today;1/16/2009, Vol. 20 Issue 10, p10 

    This section offers news briefs on clinical trials. BioSyntech Inc. will conclude enrollment for the Canadian-European pivotal trial of its cartilage repair device BST-CarGel in February 2009. Encouraging results of Kyowa Hakko Kirin Co. Limited's Phase II trial of its anti-Parkinson's disease...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics